Vertex Inc. Cl A (VERX) News

Vertex Inc. Cl A (VERX): $19.02

0.02 (+0.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter VERX News Items

VERX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VERX News Highlights

  • VERX's 30 day story count now stands at 15.
  • Over the past 27 days, the trend for VERX's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • INSG, SKIN and VC are the most mentioned tickers in articles about VERX.

Latest VERX News From Around the Web

Below are the latest news stories about Vertex Inc that investors may wish to consider to help them evaluate VERX as an investment opportunity.

Genome Editing Market Size To Reach USD 15072.3 Million by 2025 | Top Key Players Sangamo Therapeutics, ToolGen, Vertex, CRISPR Therapeutics, Precision Biosciences, Oxford Genetics

Global Genome Editing Market is valued at USD 5052.2 Million in 2020 and expected to reach USD 15072.3 Million by 2025 with the CAGR of 16.9% over the forecast period. Global Genome Editing Market: Global Size, Trends, Competitive, Historical & Forecast

OpenPR | September 22, 2021

Twenty-two insightful venture capital sessions reviewing the Asia growth story

Our 35 top speakers represent prominent VC firms and startups such as Vertex, Lippo, Blume, Sequoia India, PropertyGuru, Ajaib and more.

DealStreetAsia | September 21, 2021

Vertex Energy, Inc.: Vertex Energy Receives Request for Additional Information from the U.S. Federal Trade Commission Regarding Its Pending Asset Divestiture to Safety-Kleen Systems, Inc.

HOUSTON, TX / ACCESSWIRE / September 21, 2021 / Vertex Energy, Inc. (NASDAQ:VTNR) ("Vertex Energy", "Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined prod

FinanzNachrichten | September 21, 2021

Strength Seen in Vertex (VERX): Can Its 9.8% Jump Turn into More Strength?

Vertex (VERX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | September 17, 2021

Ayu Health snags funding from Vertex, Stellaris and 10 India deal updates

Ayu Health expects to grow its business 10x in FY22.

DealStreetAsia | September 16, 2021

Vertex Energy, Inc.: Vertex Energy Commences Restart Operations at the Marrero Refinery

HOUSTON, TX / ACCESSWIRE / September 10, 2021 / Vertex Energy, Inc. (NASDAQ:VTNR), ("Vertex Energy", "Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined pro

FinanzNachrichten | September 10, 2021

Vertex Energy Commences Restart Operations at the Marrero Refinery

HOUSTON, TX / ACCESSWIRE / September 10, 2021 / Vertex Energy, Inc. (NASDAQ:VTNR), ("Vertex Energy", "Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, today provided an update on the status of

Wallstreet:Online | September 10, 2021

Cramer Gives His Opinion On Service Corporation, Vertex And More

On CNBC''s "Mad Money Lightning Round," Jim Cramer said he isn''t happy with the way Inseego Corp (NASDAQ: INSG ) acts. He is beginning to believe it deserves to be trading 45% lower. Biohaven Pharmaceutical Holding Co Ltd (NYSE:

Business Insider Markets | September 10, 2021

Vertex Energy, Inc.: Vertex Energy Provides Marrero Refinery Operational Update

HOUSTON, TX / ACCESSWIRE / August 30, 2021 / Vertex Energy, Inc. (NASDAQ:VTNR)("Vertex Energy", "Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products

FinanzNachrichten | August 30, 2021

Alpha-Antitrypsin Deficiency (AATD) Market Stunning Revenues by 2028| Grifols, Kamada, Shire, CSL Behring, LFB Biotechnologies, Alnylam Pharmaceuticals, Arrow Head Pharmaceuticals, Vertex, Mereo Biopharma

Alpha-1 antitrypsin deficiency (AATD) is an inherited disease that causes an increased risk of having chronic obstructive pulmonary disease (COPD), liver disease, skin problems (panniculitis), and inflammation of the blood vessels (vasculitis). Alpha-1 antitrypsin deficiency occurs worldwide, but its prevalence varies

OpenPR | August 26, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6022 seconds.